Zkusit zdarma
TScan Therapeutics, Inc.

TScan Therapeutics, Inc.

TCRX
Cena:
$ 1.06
+0.04 (3.92%)
Valuace
70
Růst
20
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

9:25 06-05-2026

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.22 per share in line with the Z...

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

7:00 06-05-2026

Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the secon...

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

16:30 27-04-2026

WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinic...

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

7:00 08-04-2026

WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinic...

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates

9:16 04-03-2026

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.18 per share versus the Zacks C...

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

7:00 04-03-2026

Presented positive updated data from the ALLOHA ™ Phase 1 heme trial at 67 th American Society of ...

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of “Hold” from Brokerages

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of “Hold” from Brokerages

1:56 19-02-2026

TScan Therapeutics, Inc. (NASDAQ: TCRX - Get Free Report) has received an average rating of "Hold" f...

TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

17:30 06-12-2025

Treatment arm continues to demonstrate favorable relapse-free survival (HR=0. 50; p=0. 23) and overa...

TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates

TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates

9:26 12-11-2025

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share versus the Zacks C...

TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

7:00 12-11-2025

Reached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 m...

TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

7:00 05-11-2025

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinica...

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

6:30 03-11-2025

Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 D...

TScan Therapeutics to Participate in Upcoming Investor Conferences

TScan Therapeutics to Participate in Upcoming Investor Conferences

7:00 03-09-2025

WALTHAM, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinic...

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates

16:01 12-08-2025

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share in line with the Z...

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

7:00 12-08-2025

Two-year relapse data from ALLOHA™ Phase 1 heme trial to be presented by end of year Expects to do...

Squarepoint Ops LLC Makes New $59,000 Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX)

Squarepoint Ops LLC Makes New $59,000 Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX)

3:34 11-06-2025

Squarepoint Ops LLC purchased a new position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX R...

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

9:20 06-05-2025

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.26 per share versus the Zacks C...

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

7:00 06-05-2025

Updates from the PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 clinical trials anticipated by en...

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

16:53 28-04-2025

WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinic...

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

7:00 31-03-2025

WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinic...

close

TSCAN THERAPEUTICS TO HOST VIRTUAL KOL EVENT TO DISCUSS CLINICAL UPDATES FROM THE ALLOHA™ PHASE 1 TRIAL AND FUTURE MARKET OPPORTUNITIES

03-12-2025
WALTHAM, MASS., DEC. 03, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICA...
Více zde

TSCAN THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

12-11-2025
REACHED AGREEMENT WITH FDA ON PIVOTAL STUDY DESIGN FOR TSC-101 FOLLOWING PRODUCTIVE END OF PHASE 1 M...
Více zde

TSCAN THERAPEUTICS TO PARTICIPATE IN THE GUGGENHEIM 2ND ANNUAL HEALTHCARE INNOVATION CONFERENCE

05-11-2025
WALTHAM, MASS., NOV. 05, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICA...
Více zde

TSCAN THERAPEUTICS REACHES AGREEMENT WITH FDA ON PIVOTAL STUDY DESIGN FOR TSC-101 AND ANNOUNCES STRATEGIC PRIORITIZATION TO ADVANCE TSC-101 AND EXTEND CASH RUNWAY INTO H2 2027

03-11-2025
POSITIVE END OF PHASE I MEETING AND AGREEMENT REACHED WITH FDA ON PIVOTAL STUDY DESIGN FOR TSC-101 D...
Více zde

TSCAN THERAPEUTICS ANNOUNCES UPCOMING ORAL AND POSTER PRESENTATIONS AT THE AMERICAN COLLEGE OF RHEUMATOLOGY CONVERGENCE 2025

17-09-2025
HIGHLIGHTS DISCOVERY OF NOVEL TARGETS IN T CELL-DRIVEN AUTOIMMUNE DISORDERS; INITIAL FINDINGS TO BE ...
Více zde

TSCAN THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

03-09-2025
WALTHAM, MASS., SEPT. 03, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINIC...
Více zde

TSCAN THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

12-08-2025
TWO-YEAR RELAPSE DATA FROM ALLOHA™ PHASE 1 HEME TRIAL TO BE PRESENTED BY END OF YEAR EXPECTS TO DO...
Více zde

TSCAN THERAPEUTICS ANNOUNCES UPCOMING PRESENTATION AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

28-05-2025
WALTHAM, MASS., MAY 28, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL...
Více zde

TSCAN THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

06-05-2025
UPDATES FROM THE PLEXI-T™ SOLID TUMOR AND ALLOHA™ HEME PHASE 1 CLINICAL TRIALS ANTICIPATED BY EN...
Více zde

TSCAN THERAPEUTICS ANNOUNCES UPCOMING PRESENTATION AT THE AMERICAN SOCIETY OF GENE AND CELL THERAPY 28TH ANNUAL MEETING

28-04-2025
WALTHAM, MASS., APRIL 28, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINIC...
Více zde

TSCAN THERAPEUTICS TO PARTICIPATE IN THE 24TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

31-03-2025
WALTHAM, MASS., MARCH 31, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINIC...
Více zde

TSCAN THERAPEUTICS APPOINTS COMMERCIAL LEADER STEPHEN CAMIOLO AS SENIOR VICE PRESIDENT, MARKET ACCESS

27-03-2025
MR. CAMIOLO BRINGS TO TSCAN DEMONSTRATED COMMERCIAL READINESS AND CELL THERAPY LAUNCH EXPERIENCE MR....
Více zde

TSCAN THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

05-03-2025
PRESENTED UPDATED DATA FROM ONGOING ALLOHA™ PHASE 1 HEME TRIAL AT THE 66 TH ASH ANNUAL MEETING AND...
Více zde

TSCAN THERAPEUTICS ANNOUNCES UPCOMING PRESENTATION AT THE TD COWEN 45TH ANNUAL HEALTH CARE CONFERENCE

27-02-2025
WALTHAM, MASS., FEB. 27, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICA...
Více zde

TSCAN THERAPEUTICS TO PARTICIPATE IN THE H.C. WAINWRIGHT 3RD ANNUAL CELL THERAPY VIRTUAL CONFERENCE

18-02-2025
WALTHAM, MASS., FEB. 18, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICA...
Více zde

TSCAN THERAPEUTICS ANNOUNCES $30 MILLION REGISTERED DIRECT OFFERING AT A 37% PREMIUM

26-12-2024
WALTHAM, MASS., DEC. 26, 2024 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICA...
Více zde

TSCAN THERAPEUTICS REFINANCES EXISTING CONVERTIBLE DEBT FACILITY WITH TERM LOAN FOR UP TO $52.5 MILLION FROM SILICON VALLEY BANK

23-12-2024
NEW NON-DILUTIVE STRUCTURE REPLACES EXISTING CONVERTIBLE FACILITY MATURING IN 2026, AND EXTENDS LOAN...
Více zde

TSCAN THERAPEUTICS TO PRESENT UPDATED DATA FROM THE ONGOING ALLOHA™ PHASE 1 HEME TRIAL DURING ORAL SESSION AT THE 66TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING AND EXPOSITION

09-12-2024
TO DATE, EVENT-FREE SURVIVAL STRONGLY FAVORS THE TREATMENT ARM (HR=0.30; P=0.04), AND TREATMENT-ARM ...
Více zde

TSCAN THERAPEUTICS NAMED A TOP PLACE TO WORK BY THE BOSTON GLOBE FOR THREE CONSECUTIVE YEARS

05-12-2024
WALTHAM, MASS., DEC. 05, 2024 (GLOBE NEWSWIRE) --  TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINI...
Více zde

TSCAN THERAPEUTICS TO HOST VIRTUAL KOL EVENT TO DISCUSS CLINICAL UPDATES FROM THE ALLOHA™ PHASE 1 TRIAL AND HEME DEVELOPMENT STRATEGY

02-12-2024
COMPANY TO ALSO PROVIDE AN UPDATE ON PLEXI-T™ PHASE 1 SOLID TUMOR TRIAL COMPANY TO ALSO PROVIDE AN...
Více zde

TSCAN THERAPEUTICS ANNOUNCES UPCOMING ORAL PRESENTATION OF DATA FROM THE ALLOHA™ PHASE 1 HEME TRIAL AT THE 66TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING AND EXPOSITION

05-11-2024
ALL TSC-TREATED PATIENTS WERE RELAPSE-FREE AND MRD NEGATIVE AS OF DATA CUTOFF TSC-100 AND TSC-101 DE...
Více zde

TSCAN THERAPEUTICS ANNOUNCES UPCOMING PRESENTATIONS AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER 39TH ANNUAL MEETING

04-10-2024
WALTHAM, MASS., OCT. 04, 2024 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICA...
Více zde

TSCAN THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

29-08-2024
WALTHAM, MASS., AUG. 29, 2024 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICA...
Více zde

TSCAN THERAPEUTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

12-08-2024
FDA GRANTS RMAT DESIGNATION TO TSC-100 AND TSC-101 FOR THE TREATMENT OF PATIENTS WITH AML, ALL, AND ...
Více zde

TSCAN THERAPEUTICS ANNOUNCES UPDATES TO ITS BOARD OF DIRECTORS

14-06-2024
GARRY A. NICHOLSON, AN EXPERIENCED EXECUTIVE WITH REGULATORY AND COMMERCIAL EXPERTISE, JOINS THE BOA...
Více zde

TSCAN THERAPEUTICS ANNOUNCES UPCOMING PRESENTATION AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

30-05-2024
WALTHAM, MASS., MAY 30, 2024 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL...
Více zde

TSCAN THERAPEUTICS RECEIVES FDA'S REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR ITS TWO LEAD TCR-T THERAPY CANDIDATES FOR THE TREATMENT OF HEME MALIGNANCIES

29-05-2024
RMAT DESIGNATION GRANTED FOR BOTH TSC-100 AND TSC-101 FOR THE TREATMENT OF PATIENTS WITH AML, ALL, A...
Více zde

TSCAN THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

13-05-2024
FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF SOLID TUMORS; INITIAL DATA ANTICI...
Více zde

TSCAN THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL EVALUATING TCR-T THERAPY FOR THE TREATMENT OF SOLID TUMORS

09-05-2024
PATIENT DOSED WITH TSC-20 3 -A0201 TARGETING CANCER-ASSOCIATED ANTIGEN PRAME ON-TRACK TO REPORT INIT...
Více zde

TSCAN THERAPEUTICS ANNOUNCES UPCOMING PRESENTATIONS AT THE 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING

24-04-2024
WALTHAM, MASS., APRIL 24, 2024 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINIC...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-01-12 00:00:008-KStáhnout
2025-11-26 00:00:008-KStáhnout
2025-11-12 00:00:008-KStáhnout
2025-11-12 00:00:0010-QStáhnout
2025-11-03 00:00:008-KStáhnout
2025-09-09 01:00:008-KStáhnout
2025-09-09 00:00:008-KStáhnout
2025-08-20 01:00:008-KStáhnout
2025-08-20 00:00:008-KStáhnout
2025-08-12 01:00:008-KStáhnout
2025-08-12 01:00:0010-QStáhnout
2025-08-12 00:00:008-KStáhnout
2025-08-12 00:00:0010-QStáhnout
2025-07-02 01:00:008-KStáhnout
2025-07-02 00:00:008-KStáhnout
2025-05-06 01:00:008-KStáhnout
2025-05-06 01:00:0010-QStáhnout
2025-05-06 00:00:008-KStáhnout
2025-05-06 00:00:0010-QStáhnout
2025-03-05 00:00:008-KStáhnout
2025-03-05 00:00:0010-KStáhnout
2025-03-04 23:00:008-KStáhnout
2025-03-04 23:00:0010-KStáhnout
2024-12-26 00:00:008-KStáhnout
2024-12-25 23:00:008-KStáhnout
2024-12-23 00:00:008-KStáhnout
2024-12-22 23:00:008-KStáhnout
2024-12-10 00:00:008-KStáhnout
2024-12-09 23:00:008-KStáhnout
2024-11-21 00:00:008-KStáhnout
2024-11-20 23:00:008-KStáhnout
2024-11-01 00:00:008-KStáhnout
2024-10-31 23:00:008-KStáhnout
2024-08-12 01:00:008-KStáhnout
2024-08-12 01:00:0010-QStáhnout
2024-08-12 00:00:008-KStáhnout
2024-08-12 00:00:0010-QStáhnout
2024-06-14 01:00:008-KStáhnout
2024-06-14 00:00:008-KStáhnout
2024-05-13 01:00:008-KStáhnout
2024-05-13 01:00:0010-QStáhnout
2024-05-13 00:00:008-KStáhnout
2024-05-13 00:00:0010-QStáhnout
2024-04-17 01:00:008-KStáhnout
2024-04-17 00:00:008-KStáhnout
2024-04-16 01:00:008-KStáhnout
2024-04-16 00:00:008-KStáhnout
2024-04-08 01:00:008-KStáhnout
2024-04-08 00:00:008-KStáhnout
2024-03-06 00:00:008-KStáhnout
2024-03-06 00:00:0010-KStáhnout
2024-03-05 23:00:008-KStáhnout
2024-03-05 23:00:0010-KStáhnout
2024-01-29 00:00:008-KStáhnout
2024-01-28 23:00:008-KStáhnout
2023-12-11 00:00:008-KStáhnout
2023-12-10 23:00:008-KStáhnout
2023-12-07 00:00:008-KStáhnout
2023-12-06 23:00:008-KStáhnout
2023-11-09 00:00:008-KStáhnout
2023-11-09 00:00:0010-QStáhnout
2023-11-08 23:00:008-KStáhnout
2023-11-08 23:00:0010-QStáhnout
2023-08-10 01:00:008-KStáhnout
2023-08-10 01:00:0010-QStáhnout
2023-08-10 00:00:008-KStáhnout
2023-08-10 00:00:0010-QStáhnout
2023-07-25 01:00:008-KStáhnout
2023-07-25 00:00:008-KStáhnout
2023-06-29 01:00:008-KStáhnout
2023-06-29 00:00:008-KStáhnout
2023-06-16 01:00:008-KStáhnout
2023-06-16 00:00:008-KStáhnout
2023-05-31 01:00:008-KStáhnout
2023-05-31 00:00:008-KStáhnout
2023-05-17 01:00:008-KStáhnout
2023-05-17 00:00:008-KStáhnout
2023-05-16 01:00:008-KStáhnout
2023-05-16 00:00:008-KStáhnout
2023-05-10 01:00:008-KStáhnout
2023-05-10 01:00:0010-QStáhnout
2023-05-10 00:00:008-KStáhnout
2023-05-10 00:00:0010-QStáhnout
2023-05-09 01:00:008-KStáhnout
2023-05-09 00:00:008-KStáhnout
2023-04-10 01:00:008-KStáhnout
2023-04-10 00:00:008-KStáhnout
2023-03-31 01:00:008-KStáhnout
2023-03-31 00:00:008-KStáhnout
2023-03-08 00:00:008-KStáhnout
2023-03-08 00:00:0010-KStáhnout
2023-03-07 23:00:008-KStáhnout
2023-03-07 23:00:0010-KStáhnout
2023-01-23 00:00:008-KStáhnout
2023-01-22 23:00:008-KStáhnout
2022-11-09 00:00:008-KStáhnout
2022-11-09 00:00:0010-QStáhnout
2022-11-08 23:00:008-KStáhnout
2022-11-08 23:00:0010-QStáhnout
2022-09-12 01:00:008-KStáhnout
2022-09-12 00:00:008-KStáhnout
2022-08-10 01:00:008-KStáhnout
2022-08-10 01:00:0010-QStáhnout
2022-08-10 00:00:008-KStáhnout
2022-08-10 00:00:0010-QStáhnout
2022-07-07 01:00:008-KStáhnout
2022-07-07 00:00:008-KStáhnout
2022-06-03 01:00:008-KStáhnout
2022-06-03 00:00:008-KStáhnout
2022-05-31 01:00:008-KStáhnout
2022-05-31 00:00:008-KStáhnout
2022-05-12 01:00:0010-QStáhnout
2022-05-12 00:00:0010-QStáhnout
2022-05-09 01:00:008-KStáhnout
2022-05-09 00:00:008-KStáhnout
2022-03-09 00:00:008-KStáhnout
2022-03-09 00:00:0010-KStáhnout
2022-03-08 23:00:008-KStáhnout
2022-03-08 23:00:0010-KStáhnout
2022-01-24 00:00:008-KStáhnout
2022-01-23 23:00:008-KStáhnout
2021-12-02 00:00:008-KStáhnout
2021-12-01 23:00:008-KStáhnout
2021-11-10 00:00:008-KStáhnout
2021-11-10 00:00:0010-QStáhnout
2021-11-09 23:00:008-KStáhnout
2021-11-09 23:00:0010-QStáhnout
2021-08-19 01:00:008-KStáhnout
2021-08-19 01:00:0010-QStáhnout
2021-08-19 00:00:008-KStáhnout
2021-08-19 00:00:0010-QStáhnout
2021-07-20 01:00:008-KStáhnout
2021-07-20 00:00:008-KStáhnout
preloader